Kadimastem - Stem Cell to Cure Diseases

News & Events > Press Releases

Successful Public Offering for Kadimastem

May. 15, 2018
Raised NIS 2.8M at a Premium to the Market Price

Kadimastem Successfully Raised NIS 15.6M in Rights Offering

Dec. 17, 2017
Company stakeholders invested NIS 6.3M

A Vote of Confidence in Kadimastem: Senior Scientists from the Weizmann Institute Invest in the Company

Aug. 13, 2017
Prof. Ruth Arnon and Prof. Michel Revel to Invest NIS 720K in the Company

Kadimastem Controlling Shareholder to Invest NIS 3.5M by Way of Private Placement

Jul. 9, 2017
In the past month, stakeholders have invested in the company NIS 5.6M

2017 Innovation Authority Budget Approved for Kadimastem: NIS 12 M for ALS Project

Jun. 4, 2017
This is the largest budget for ALS that Kadimastem has received yet from the Innovation Authority (formerly Office of the Chief Scientist)

Success for Kadimastem in Rights Offering;

Feb. 28, 2017
Raised NIS 7.2M 71% of the rights offered were exercised

Kadimastem Announces Strategic Collaboration with Korean Biotech Company Corestem, Including a $7M Investment in Kadimastem

Dec. 7, 2016
Corestem is the only company in the world with a cell therapy treatment for ALS which has been approved for marketing by a regulatory authority. Corestem believes in Kadimastem's technologies in the ALS and diabetes fields, and the agreement will assist in expediting Kadimastem's entry into the market

Stakeholders' Support for Kadimastem Continues: Investment of NIS 2.5M by Way of Convertible Loan

Nov. 9, 2016
If an investment agreement of $ 2M or more will be signed with a foreign company or investor, the loan will be converted in a rights offering under identical terms

Towards the Company's First Clinical Trial;

Nov. 2, 2016
Kadimastem Signs Letter of Intent with Hadassah Medical Center for Performance of the Clinical Trial in ALS

Press Releases Archive